A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder
Phase of Trial: Phase III
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Rapastinel (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Sponsors Allergan
- 23 Oct 2018 Status changed from not yet recruiting to recruiting.
- 22 Oct 2018 Planned End Date changed from 19 Dec 2020 to 25 Dec 2020.
- 22 Oct 2018 Planned primary completion date changed from 19 Dec 2020 to 25 Dec 2020.